Development of broadly reactive antibody therapeutics for SARS-CoV-2
Drug Delivery System
; 37(5), 2022.
Article
in Japanese
| ProQuest Central | ID: covidwho-2317392
ABSTRACT
Various antibody therapeutics has been developed for the treatment and suppression of the 2019 outbreak of novel coronavirus(SARS-CoV-2)infection. A major limitation in the development of SARS-CoV-2 neutralizing antibodies is the occurrence and spread of escape variants that have mutations in the spike glycoprotein. The coronaviruses are carried by various wild animals, domestic animals, and pets, and there have been cases of Severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus transmission from animals to people, resulting in a large spread of infection in people. There is also a possibility that cross-species transmission of SARS-CoV-2 may occur in the future. Considering these factors, the development of antibody therapeutics with broad cross-reactivity against SARS-CoV-2 variants and other coronaviruses is required.Alternate抄録2019年に発生した新型コロナウイルス(SARS-CoV-2)感染症の治療や発症抑制のためにさまざまな抗体医薬の開発が進められている。SARS-CoV-2中和抗体の開発で大きな障壁となるのが、スパイク糖タンパク質に変異をもつ変異株の発生と感染拡大である。またコロナウイルスは多くの野生動物や家畜、愛玩動物が保有しており、これまでにも重篤呼吸器症候群コロナウイルスや中東呼吸器症候群コロナウイルスが動物からヒトへ伝播して大きく感染が広がったケースがある。SARS-CoV-2についても動物が起源であると考えられており、今後も種を越えた伝播が発生する可能性が考えられる。これらを踏まえて、SARS-CoV-2変異株や類縁コロナウイルスに対する交差反応性に優れた抗体医薬の開発が求められる。
Pharmacy And Pharmacology; Broadly neutralizing antibody; SARS-CoV-2; infectious disease; Coronaviruses; Antibodies; Cross-reactivity; Animals; Spike glycoprotein; Pets; Severe acute respiratory syndrome coronavirus 2; Domestic animals; Viral diseases; Drug development; Glycoproteins; Respiratory diseases; Coronaviridae
Full text:
Available
Collection:
Databases of international organizations
Database:
ProQuest Central
Language:
Japanese
Journal:
Drug Delivery System
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS